Suppr超能文献

Ki-67和增殖细胞核抗原(PCNA)在复发性胆脂瘤中的预测作用

Predictive Role of Ki-67 and Proliferative-Cell Nuclear Antigen (PCNA) in Recurrent Cholesteatoma.

作者信息

Araz Server Ela, Kalaycık Ertugay Çiğdem, Baykal Koca Sevim, Longur Ecem Sevim, Yiğit Özgür, Demirhan Hasan, Çakır Yasemin

机构信息

Department of Otorhinolaryngology, İstanbul Training and Research Hospital, İstanbul, Turkey.

Department of Pathology, İstanbul Training and Research Hospital, İstanbul, Turkey.

出版信息

J Int Adv Otol. 2019 Apr;15(1):38-42. doi: 10.5152/iao.2018.4976.

Abstract

OBJECTIVES

To investigate the potential use of Ki-67 and pronuclear cell antigen (PCNA) as indicators of recurrent cholesteatoma.

MATERIAL AND METHODS

Patients who had been diagnosed with cholesteatoma and who had undergone canal wall-down mastoidectomy were included in this study. Subjects were divided into two groups: recurrent and non-recurrent (i.e., cases without recurrence for at least 2 years). Ossicular pathologies were recorded. Histopathologic specimens were stained for Ki-67 and PCNA and the percentages of stained cells were calculated.

RESULTS

Neither group demonstrated a significant difference in terms of total Ki-67 per cell, Ki-67-stained cell counts, Ki-67-staining percentages, total PCNA per cell, PCNA-stained cell counts, or PCNA-staining percentages (p>0.05). No significant relationship was noted between the staining percentages for either Ki-67 or PCNA and the incudostapedial involvement (p>0.05); however, a significant relationship was noted between Ki-67 staining and malleus involvement (p<0.05).

CONCLUSION

Although the recurrent and non-recurrent cholesteatoma groups showed no significant differences in terms of the percentages of stained cells for either Ki-67 or PCNA, we detected high Ki-67 staining in the malleus involvement group. We concluded that cell-proliferation markers could not be defined as indicators of recurrence of cholesteatoma, but they could be defined as indicators of destructive patterns of this disease.

摘要

目的

研究Ki-67和原核细胞抗原(PCNA)作为复发性胆脂瘤指标的潜在用途。

材料与方法

本研究纳入了已被诊断为胆脂瘤且接受了开放式乳突根治术的患者。受试者分为两组:复发性和非复发性(即至少2年未复发的病例)。记录听骨链病变情况。对组织病理学标本进行Ki-67和PCNA染色,并计算染色细胞的百分比。

结果

两组在每细胞总Ki-67、Ki-67染色细胞计数、Ki-67染色百分比、每细胞总PCNA、PCNA染色细胞计数或PCNA染色百分比方面均无显著差异(p>0.05)。Ki-67或PCNA的染色百分比与砧镫关节受累之间未发现显著相关性(p>0.05);然而,Ki-67染色与锤骨受累之间存在显著相关性(p<0.05)。

结论

尽管复发性和非复发性胆脂瘤组在Ki-67或PCNA的染色细胞百分比方面无显著差异,但我们在锤骨受累组中检测到高Ki-67染色。我们得出结论,细胞增殖标志物不能被定义为胆脂瘤复发的指标,但它们可以被定义为该疾病破坏模式的指标。

相似文献

1
2
Some markers of proliferative activity in cholesteatoma epithelium in adults.
Med Sci Monit. 2006 Aug;12(8):CR337-40. Epub 2006 Jul 12.
3
[Evaluation of Ki-67 expression in recurrent cases of cholesteatoma].
Kulak Burun Bogaz Ihtis Derg. 2007;17(2):65-9.
4
Comparison of immunostainings for proliferating cell nuclear antigen and Ki-67 in human extraocular lesions.
Graefes Arch Clin Exp Ophthalmol. 1997 Dec;235(12):767-72. doi: 10.1007/BF02332861.
6
Prognostic significance of Ki-67 (MIB1), PCNA and p53 in cancer of the oropharynx and oral cavity.
Oral Oncol. 1999 Nov;35(6):583-9. doi: 10.1016/s1368-8375(99)00041-x.
9
PCNA/AgNOR and Ki-67/AgNOR double staining in oral squamous cell carcinoma.
J Oral Pathol Med. 1999 Nov;28(10):438-41. doi: 10.1111/j.1600-0714.1999.tb02103.x.

引用本文的文献

3
Comparison of Tissue Factors in the Ontogenetic Aspects of Human Cholesteatoma.
Diagnostics (Basel). 2024 Mar 21;14(6):662. doi: 10.3390/diagnostics14060662.
4
Recurrence in cholesteatoma surgery: what have we learnt and where are we going? A narrative review.
Acta Otorhinolaryngol Ital. 2023 Apr;43(Suppl 1):S48-S55. doi: 10.14639/0392-100X-suppl.1-43-2023-06.
6
Morphopathogenesis of Adult Acquired Cholesteatoma.
Medicina (Kaunas). 2023 Feb 7;59(2):306. doi: 10.3390/medicina59020306.
7
Endotyping of Cholesteatoma: Which Molecular Biomarkers? A Systematic Review.
J Pers Med. 2022 Aug 21;12(8):1347. doi: 10.3390/jpm12081347.

本文引用的文献

1
Incidence, 10-year recidivism rate and prognostic factors for cholesteatoma.
J Laryngol Otol. 2017 Apr;131(4):319-328. doi: 10.1017/S0022215117000299.
2
Cytokeratin 13, Cytokeratin 17, and Ki-67 Expression in Human Acquired Cholesteatoma and Their Correlation With Its Destructive Capacity.
Clin Exp Otorhinolaryngol. 2017 Sep;10(3):213-220. doi: 10.21053/ceo.2016.01263. Epub 2017 Jan 12.
3
The role of bone resorption in the etiopathogenesis of acquired middle ear cholesteatoma.
Eur Arch Otorhinolaryngol. 2017 May;274(5):2071-2078. doi: 10.1007/s00405-016-4422-6. Epub 2016 Dec 16.
4
Acquired cholesteatoma epithelial hyperproliferation: Roles of cell proliferation signal pathways.
Laryngoscope. 2016 Aug;126(8):1923-30. doi: 10.1002/lary.25834. Epub 2016 Mar 15.
5
Analysis of histopathological aspects and bone destruction characteristics in acquired middle ear cholesteatoma of pediatric and adult patients.
Int J Pediatr Otorhinolaryngol. 2016 Mar;82:73-7. doi: 10.1016/j.ijporl.2016.01.008. Epub 2016 Jan 13.
6
The disease recurrence rate after the canal wall up or canal wall down technique in adults.
Laryngoscope. 2016 Apr;126(4):980-7. doi: 10.1002/lary.25591. Epub 2015 Sep 25.
7
Surgical technique and recurrence in cholesteatoma: a meta-analysis.
Audiol Neurootol. 2013;18(3):135-42. doi: 10.1159/000346140. Epub 2013 Jan 12.
9
Identification of Id1 in acquired middle ear cholesteatoma.
Arch Otolaryngol Head Neck Surg. 2008 Mar;134(3):306-10. doi: 10.1001/archotol.134.3.306.
10
[Evaluation of Ki-67 expression in recurrent cases of cholesteatoma].
Kulak Burun Bogaz Ihtis Derg. 2007;17(2):65-9.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验